Durham, NC – [November 11, 2024] – BioAgilytix, a leading global bioanalytical laboratory, is proud to announce its inclusion in the Triangle Business Journal’s prestigious Fast 50 Awards for 2024. This recognition highlights the company’s significant growth, innovation, and continued commitment to advancing science in the biopharmaceutical industry. 

The Fast 50 Awards honor the fastest-growing, privately held companies in the Triangle region based on revenue growth and profitability over the last three years. BioAgilytix’s inclusion in the 2024 list showcases its remarkable achievements in the field of bioanalytics, which has been driven by strategic investments, key leadership hires, and global lab expansions. This is the 12^th time that BioAgilytix has been recognized by the Triangle Business Journal’sFast 50 awards 

“We are thrilled to be recognized among the Triangle’s top-performing companies,” said Davide Molho, CEO of BioAgilytix. “This award is a testament to the dedication of our team and our ongoing mission to provide world-class bioanalytical support to our partners in the pharmaceutical and biotech industries. Our growth is fueled by innovation and a relentless commitment to quality, and we’re excited to continue our journey of helping bring new therapies to market.” 

In the past year, BioAgilytix has significantly expanded its operations, including new investments in its labs in Hamburg, Melbourne, and Durham, and the addition of new senior leadership, such as Mehul Patel as Chief Information Officer, Rebecca New as Chief People Officer, and Ed Amat as Chief Growth Officer. These strategic developments have strengthened BioAgilytix’s position as a leader in bioanalytical testing for complex biologics, contributing to the company’s impressive growth trajectory. 

About BioAgilytix

BioAgilytix is the trusted partner for bioanalytical services throughout every phase of the drug development process. As a leading global bioanalytical laboratory, the company provides established and emerging pharmaceutical and biotechnology organizations with pharmacokinetic (PK), immunogenicity, biomarker, and CMC bioanalytical testing services in a GxP environment. BioAgilytix maintains state-of-the-art laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany. For more information, please visit www.bioagilytix.com.  

For more information, please contact:

Noelle Brawner
Communications Manager
BioAgilytix Labs, LLC
Noelle.brawner@bioagilytix.com